Andreas Schneeweiss
Expertise in
16
conditions

Andreas Schneeweiss

Heidelberg, BW, DE 
Expertise in
16
conditions
Heidelberg, BW, DE 

Overview

Andreas Schneeweiss practices practicing medicine in Heidelberg, Germany.

Mr. Schneeweiss is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, HER2 Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Mastectomy.

He is actively involved in clinical research, co-authoring 568 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Heidelberg, BW, Germany
Other Locations
Salem, BW, Germany
Luebeck, SH, Germany
Germany
Hamburg, HH, Germany
Munich, BY, Germany
Offenbach, HE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin
Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin
Enrollment Status: Completed
Publish Date: March 06, 2024
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Abraxane, Atezolizumab, Anthra
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Enrollment Status: Completed
Publish Date: July 13, 2017
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

568 Total Publications

Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine care.
Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine care.
Journal: ESMO real world data and digital oncology
Published: April 03, 2026

Frequently Asked Questions about Andreas Schneeweiss

Is Andreas Schneeweiss a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Andreas Schneeweiss is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Andreas Schneeweiss participate in research or clinical trials?

Yes. Andreas Schneeweiss has published 568 articles and abstracts on conditions like Breast Cancer. You can view a list of Andreas Schneeweiss's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schneeweiss's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile